Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients
International Journal of Dermatology 2025;64:1401–1408 Doi: 10.1111/ijd.17814
This study by Sobotkova et al. confirmed the similar efficacy and overall safety of biological treatment for psoriasis in older and younger adult patients. Authors compared a large cohort of older adults during the first year of biological treatment for psoriasis to younger adult patients with similar characteristics to advance knowledge about the biologic treatment of psoriasis in older patients.
Despite more comorbidities, the incidence of SAEs did not increase in older patients. However, older patients had a lower survival rate after biologic treatment for psoriasis, particularly in those treated with adalimumab.
